{"id":25486,"date":"2024-07-16T16:21:40","date_gmt":"2024-07-16T14:21:40","guid":{"rendered":"https:\/\/ggba.swiss\/asceneuron-raises-usd-100-million-to-advance-alzheimers-treatment\/"},"modified":"2024-07-16T16:24:20","modified_gmt":"2024-07-16T14:24:20","slug":"asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/","title":{"rendered":"Asceneuron l\u00e8ve USD 100 millions en faveur du traitement de la maladie d’Alzheimer"},"content":{"rendered":"\n

Asceneuron<\/a>, une soci\u00e9t\u00e9 de biotechnologie au stade clinique bas\u00e9e \u00e0 Lausanne, a cl\u00f4tur\u00e9 avec succ\u00e8s un tour de financement de s\u00e9rie C sursouscrit, levant ainsi USD 100 millions. Ce tour de table a \u00e9t\u00e9 men\u00e9 par Novo Holdings<\/a>, avec de nouveaux investissements d’EQT Life Sciences – LSP Dementia Fund<\/a>, OrbiMed<\/a> et SR One<\/a>, aux c\u00f4t\u00e9s des investisseurs existants M Ventures<\/a>, Sofinnova Partners<\/a>, GSK Equities Investments Limited<\/a> et Johnson & Johnson Innovation – JJDC, Inc<\/a>.<\/p>\n\n\n\n

Cet investissement substantiel servira \u00e0 faire progresser le d\u00e9veloppement clinique des inhibiteurs d’OGA innovants d’Asceneuron pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives. L’accent sera mis sur l’avancement de l’ASN51, une petite mol\u00e9cule orale inhibitrice de l’OGA, dans les essais cliniques de phase 2 pour la maladie d’Alzheimer. L’ASN51 est con\u00e7u pour emp\u00eacher l’agr\u00e9gation de la prot\u00e9ine tau, qui est impliqu\u00e9e dans la progression de la maladie d’Alzheimer, ce qui pourrait ralentir la progression de la maladie. En outre, l’inhibition de l’OGA s’est r\u00e9v\u00e9l\u00e9e prometteuse dans la pr\u00e9vention de l’agr\u00e9gation des prot\u00e9ines dans d’autres maladies neurod\u00e9g\u00e9n\u00e9ratives, notamment la maladie de Parkinson et la scl\u00e9rose lat\u00e9rale amyotrophique.<\/p>\n\n\n\n

\u00ab La maladie d’Alzheimer est en train de vivre un moment de transformation. Des millions de personnes sont touch\u00e9es par cette maladie d\u00e9vastatrice et il n’existe que tr\u00e8s peu d’options th\u00e9rapeutiques. Les biomarqueurs valid\u00e9s permettent un d\u00e9veloppement plus cibl\u00e9 et plus rapide. Nous assistons actuellement \u00e0 l’approbation des premi\u00e8res th\u00e9rapies injectables \u00e0 base d’anticorps qui modifient la maladie. La petite mol\u00e9cule orale innovante d’Asceneuron ciblant la prot\u00e9ine tau intracellulaire offre la possibilit\u00e9 d’un changement de paradigme dans la mani\u00e8re dont cette maladie neurod\u00e9g\u00e9n\u00e9rative est trait\u00e9e \u00bb, a d\u00e9clar\u00e9 Naveed Siddiqi, MD, Senior Partner, Venture Investments, Novo Holding.<\/p>\n\n\n\n

Asceneuron a d\u00e9j\u00e0 r\u00e9alis\u00e9 cinq essais cliniques de phase 1 d\u00e9montrant une absorption compl\u00e8te du syst\u00e8me nerveux central et une occupation \u00e9lev\u00e9e de l’enzyme OGA. La soci\u00e9t\u00e9 pr\u00e9voit de lancer son premier essai clinique de phase 2 dans le courant de l’ann\u00e9e, marquant ainsi une \u00e9tape importante dans sa mission de d\u00e9veloppement de traitements efficaces pour la maladie d’Alzheimer.<\/p>\n\n\n\n

Barbara Angehrn Pavik, CEO d’Asceneuron, a d\u00e9clar\u00e9 : \u00ab Ce syndicat d’investisseurs de haut niveau dans le domaine des sciences de la vie confirme le potentiel de notre pipeline d’inhibiteurs d’OGA et notre leadership dans le domaine des tauopathies. Nous sommes ravis de faire avancer notre produit phare, l’ASN51, en phase 2 de d\u00e9veloppement clinique, car nous savons qu’il pourrait \u00e9largir consid\u00e9rablement les options th\u00e9rapeutiques pour les patients atteints de la maladie d’Alzheimer. \u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"

Asceneuron a obtenu un financement de s\u00e9rie C de USD 100 millions pour poursuivre sa mission de d\u00e9veloppement d’inhibiteurs de l’OGA pour les maladies neurod\u00e9g\u00e9n\u00e9ratives telles que la maladie d’Alzheimer.<\/p>\n","protected":false},"author":6,"featured_media":25483,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1188,1171],"class_list":["post-25486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"\nAsceneuron l\u00e8ve USD 100M pour traiter la maladie d'Alzheimer<\/title>\n<meta name=\"description\" content=\"Asceneuron a lev\u00e9 USD 100 millions pour poursuivre sa mission de d\u00e9veloppement d'inhibiteurs pour traiter la maladie d'Alzheimer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asceneuron l\u00e8ve USD 100M pour traiter la maladie d'Alzheimer\" \/>\n<meta property=\"og:description\" content=\"Asceneuron a lev\u00e9 USD 100 millions pour poursuivre sa mission de d\u00e9veloppement d'inhibiteurs pour traiter la maladie d'Alzheimer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-16T14:21:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-16T14:24:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Asceneuron l\u00e8ve USD 100 millions en faveur du traitement de la maladie d’Alzheimer\",\"datePublished\":\"2024-07-16T14:21:40+00:00\",\"dateModified\":\"2024-07-16T14:24:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/\"},\"wordCount\":499,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/\",\"name\":\"Asceneuron l\u00e8ve USD 100M pour traiter la maladie d'Alzheimer\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg\",\"datePublished\":\"2024-07-16T14:21:40+00:00\",\"dateModified\":\"2024-07-16T14:24:20+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Asceneuron a lev\u00e9 USD 100 millions pour poursuivre sa mission de d\u00e9veloppement d'inhibiteurs pour traiter la maladie d'Alzheimer.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Cette derni\u00e8re lev\u00e9e de fonds confirme le potentiel d'Asceneuron \u00e0 avoir un impact significatif sur la vie des patients souffrant de la maladie d'Alzheimer et d'autres maladies apparent\u00e9es.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asceneuron l\u00e8ve USD 100 millions en faveur du traitement de la maladie d’Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Asceneuron l\u00e8ve USD 100M pour traiter la maladie d'Alzheimer","description":"Asceneuron a lev\u00e9 USD 100 millions pour poursuivre sa mission de d\u00e9veloppement d'inhibiteurs pour traiter la maladie d'Alzheimer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/","og_locale":"fr_FR","og_type":"article","og_title":"Asceneuron l\u00e8ve USD 100M pour traiter la maladie d'Alzheimer","og_description":"Asceneuron a lev\u00e9 USD 100 millions pour poursuivre sa mission de d\u00e9veloppement d'inhibiteurs pour traiter la maladie d'Alzheimer.","og_url":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-07-16T14:21:40+00:00","article_modified_time":"2024-07-16T14:24:20+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Asceneuron l\u00e8ve USD 100 millions en faveur du traitement de la maladie d’Alzheimer","datePublished":"2024-07-16T14:21:40+00:00","dateModified":"2024-07-16T14:24:20+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/"},"wordCount":499,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg","keywords":["Biotech","Financing","Healthcare","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/","url":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/","name":"Asceneuron l\u00e8ve USD 100M pour traiter la maladie d'Alzheimer","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg","datePublished":"2024-07-16T14:21:40+00:00","dateModified":"2024-07-16T14:24:20+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Asceneuron a lev\u00e9 USD 100 millions pour poursuivre sa mission de d\u00e9veloppement d'inhibiteurs pour traiter la maladie d'Alzheimer.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/07\/Asceneuron-Alzheimer-2360x1622-1.jpeg","width":2360,"height":1622,"caption":"Cette derni\u00e8re lev\u00e9e de fonds confirme le potentiel d'Asceneuron \u00e0 avoir un impact significatif sur la vie des patients souffrant de la maladie d'Alzheimer et d'autres maladies apparent\u00e9es."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/asceneuron-leve-usd-100-millions-en-faveur-du-traitement-de-la-maladie-dalzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Asceneuron l\u00e8ve USD 100 millions en faveur du traitement de la maladie d’Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=25486"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25486\/revisions"}],"predecessor-version":[{"id":25488,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25486\/revisions\/25488"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/25483"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=25486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=25486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=25486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}